Background
==========

Systemic sclerosis (SSc) is characterized by widespread tissue fibrosis including the myocardium. Diffuse myocardial fibrosis can be detected non-invasively by extracellular volume (ECV) imaging based on pre- and postcontrast T1 measurements using cardiovascular magnetic resonance (CMR). We hypothesized that multiparametric CMR, including T1 mapping, can detect subclinical myocardial involvement and provide a comprehensive cardiac assessment in patients with SSc.

Methods
=======

19 SSc patients (18 female, mean age 55 ± 10 years) and 20 controls (19 female, mean age 56 ± 8 years) without overt cardiovascular disease underwent CMR at 1.5T. CMR assessments included late gadolinium enhancement (LGE) \[IV gadoterate meglumine at 0.15 mmol/kg\], T1 mapping pre- and postcontrast, cine, tagging, and T2-weighted imaging.

Results
=======

Focal fibrosis on LGE was found in 10 SSc patients (53%) but none of controls. Evidence of diffuse myocardial fibrosis in SSc patients was supported by significantly higher precontrast T1 values (1007 ± 29 vs. 958 ± 20 ms, p \< 0.001) and expansion of ECV (35.4 ± 4.8 vs. 27.6 ± 2.5 %, p \< 0.001). Regardless of any regional fibrosis, indices of diffuse myocardial fibrosis were significantly elevated in SSc and correlated with disease activity and severity. Although biventricular size and global function were preserved, peak systolic circumferential strain (-16.8 ± 1.6 vs. -18.6 ± 1.0, p \< 0.001) and peak diastolic strain rate (83 ± 26 vs. 114 ± 16 s-1, p \< 0.001) were impaired in SSc. Impaired myocardial systolic strain and diastolic strain rate inversely correlated with diffuse myocardial fibrosis indices. There was no evidence of myocardial edema in SSc.

Conclusions
===========

Cardiac involvement is common in SSc even in the absence of cardiac symptoms, and includes both focal and ubiquitous diffuse myocardial fibrosis; this is associated with impaired systolic and diastolic strain parameters, as well as disease activity and severity. CMR may be useful in future in the study of treatments aimed at preventing or reducing diffuse myocardial fibrosis in SSc.
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###### 

Continuous data are mean ± SD unless otherwise indicated.

  -----------------------------------------------------------------------------------------
                                                     Controls\     SSc\          P value
                                                     N = 20        N = 19        
  -------------------------------------------------- ------------- ------------- ----------
  Female sex, n (%)                                  19 (95)       18 (95)       0.74

  Age, years                                         56 ± 8        55 ± 10       0.64

  Hypertension, n (%)                                2 (10)        4 (21)        0.41

  Diabetes, n (%)                                    0             0             \-

  Hyperlipidaemia, n (%)                             4 (20)        3 (16)        0.73

  BMI, kg/m2                                         25 ± 4        27 ± 7        0.23

  SSc VDAI                                           N/A           4 ± 2         \-

  ESR, mm/hr (median, IQR)                           N/A           11 (3-18)     \-

  CRP, mg/L (median, IQR)                            3 (1-4)       5 (2-8)       0.01

  Hemoglobin (g/L)                                   13 ± 1        12 ± 1        0.05

  mRSS                                               N/A           20 ± 6        \-

  LVEDV indexed, ml/m2                               77 ± 16       69 ± 11       0.08

  LVESV indexed, ml/m2                               21 ± 5        18 ± 5        0.06

  LVEF, %                                            73 ± 5        74 ± 6        0.52

  LV Mass indexed, g/m2                              52 ± 11       51 ± 8        0.74

  LA size, mm                                        28 ± 5        37 ± 6        \< 0.001

  RVEDV indexed, ml/m2                               85 ± 19       77 ± 12       0.32

  RVESV indexed, ml/m2                               28 ± 7        25 ± 7        0.06

  RVEF, %                                            67 ± 4        67 ± 6        0.14

  Mid SA circumferential strain                      -18.6 ± 1.0   -16.8 ± 1.6   \< 0.001

  Peak diastolic circumferential strain rate (s-1)   114 ± 16      83 ± 26       \< 0.001

  Presence of LGE (%)                                0             10 (53)       \-

  Volume fraction of LGE \> 2SD (%)                  0             3.8 ± 0.4     \-

  STIR T2 Ratio                                      1.6 ± 0.5     1.7 ± 0.4     0.66
  -----------------------------------------------------------------------------------------

BMI, body mass index; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; IQR, interquartile range; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; mRSS, modified Rodnan skin score; RVEDV; right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVESD, right ventricular end-systolic volume; SA, short axis; SSc, systemic sclerosis; STIR, short Tau inversion recovery; VDAI, Valentini disease activity index of the European Scleroderma Study Group
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